Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(−) T-cells

Although lenalidomide and pomalidomide are well-established treatment options in patients with multiple myeloma, their immune-modulating effects are not fully understood. While CD8(+)CD28(−) regulatory T-cells in patients with hematologic disorders display a known immune-escape mechanism, we show th...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuber, Brigitte, Dai, Jingying, Waraich, Wjahat A., Awwad, Mohamed H.S., Engelhardt, Melanie, Schmitt, Michael, Medenhoff, Sergej, Witzens-Harig, Mathias, Ho, Anthony D., Goldschmidt, Hartmut, Hundemer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716723/
https://www.ncbi.nlm.nih.gov/pubmed/29228683
http://dx.doi.org/10.18632/oncotarget.21516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716723/
https://www.ncbi.nlm.nih.gov/pubmed/29228683
http://dx.doi.org/10.18632/oncotarget.21516

Ejemplares similares